⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 30, 2007JNCI Journal of the National Cancer Institute

Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis

View Full Paper

Ask AI

Bookmark

Share

Abstract

In patients with indolent or mantle cell lymphoma, R-chemo is superior to chemotherapy alone with respect to overall survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schulz et al. (2007) studied this question.

synapsesocial.com/papers/69dcc72d5f911386753591d8 https://doi.org/10.1093/jnci/djk152

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Original Research · 2005 · 577 citations
2Assessing the quality of controlled clinical trialsSystematic Review · 2001 · 3,360 citations
3Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).Late-Phase Clinical Trial · 2004 · 72 citations
4High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin’s Lymphoma: A Case-Matched Study From the European Bone Marrow Transplant Registry2001 · 131 citations
5Improved Survival of Follicular Lymphoma Patients in the United StatesPrognostic Study · 2005 · 264 citations